ClinicalTrials.gg
CompletedNCT03417895PASSIONUpdated Aug 7, 2024Results posted

SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy

A Phase 2 interventional study of SHR-1210 and Apatinib in Small-cell Lung Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 2 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-08-07.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 365 studies in Small Cell Lung Carcinoma with a site in China — 183 open to participants now, 215 under way, 36 of them phase 3. Small Cell Lung Carcinoma · China.

Enrollment
186th of 333
59 · median 63
Started
2018
with 15 others
Phase 2
153 of 365
70 open now
Registered
45th of 365
by date

Among the 365 studies in Small Cell Lung Carcinoma with a site in China, this one is the 186th largest by enrollment of the 333 interventional ones that give a count, is one of 16 that started in 2018, is one of 153 in phase 2, and was the 45th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

183 of the 365 studies in Small Cell Lung Carcinoma with a site in China are open now. Recruiting first, the newest first:

178 more — sign in →

All 183 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 365 studies in Small Cell Lung Carcinoma with a site in China, or all of them as a file.
02

Study summary

This is a multi-center, open-label, phase II study of intravenous (IV) SHR-1210 at 200mg,q2w in combination with Apatinib at one dose (375mg). Comparison of 3 different dose schedules in subjects with extensive-stage disease small cell lung cancer. SHR-1210 is a humanized monoclonal antibody against Programmed death 1(PD-1). Apatinib is a new kind of selective Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) tyrosine kinase inhibitor (TKI).

The study is composed of two parts. Part 1 of the study will determine the safety and tolerability of SHR-1210 in combination with Apatinib in first 6 subjects of each arm. The second phase of treatment was carried out by selecting one group of administration mode and the tolerated dose of Apatinib. Part 2 of the study will determine the safety and efficacy of SHR-1210 in combination with Apatinib in 39 subjects.

03

Conditions studied

  • Small-cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed inform consent form.
  2. Age >= 18 years and \<= 70 years.
  3. or cytologically confirmed small cell lung cancer.
  4. ED-SCLC according to Veterans Administration Lung Study Group.
  5. Radiographically progression following a platinum-based standard prior chemotherapy regimen.
  6. performance status of 0 or 1.
  7. as defined by v1.1.
  8. >= 8 weeks.
  9. Adequate hematologic and end organ function.

Exclusion criteria

Exclusion Criteria:

  1. or cytologically confirmed mixed non-small cell and small cell carcinoma.
  2. Prior exposure to therapeutic anticancer vaccines; prior exposure to any T cell co-stimulatory therapy or , including but not limited to other anti-CTLA-4, anti-PD-1, anti-PD-L1 and anti-PD-L2 antibodies.
  3. Prior exposure to anti-VEGF or anti-VEGFR therapy.
  4. Active or meningeal .
  5. third space effusion (e.g., uncontrolled pericardial effusion, ascites or pleural effusion by extraction or other treatment).
  6. Known to study drug or any of its ; known hypersensitivity to any antibody.
  7. Treatment with any other agent or participation in another clinical trial within 4 weeks prior to screening.
  8. Other conditions that the investigator thinks unsuitable in this study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    A (SHR-1210+Apatinib)

    SHR-1210 200mg, IV, Q2W and Apatinib 375mg, PO, QD

    Drug: SHR-1210 · Drug: Apatinib

  • Experimental
    B (SHR-1210+Apatinib)

    SHR-1210 200mg, IV, Q2W and Apatinib 375mg, PO, QD (5 Days on, 2 Days off)

    Drug: SHR-1210 · Drug: Apatinib

  • Experimental
    C (SHR-1210+Apatinib)

    SHR-1210 200mg, IV, Q2W and Apatinib 375mg, PO, QD (7 Days on, 7 Days off)

    Drug: SHR-1210 · Drug: Apatinib

Interventions

  • A humanized anti-PD-1 monoclonal antibody

  • A tyrosine kinase inhibitor selectively targeting VEGFR-2

06

What researchers measure

Primary outcomes

  1. Adverse Event

    Evaluation of adverse event rate according to CTCAE v4.03

    Time frame: 24 months

  2. ORR

    Objective response rate according to RECIST v1.1 (Response was assessed with CT or MRI using RECIST v1.1, Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to\<10 mm; Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Over all response:CR+PR)

    Time frame: 6 months

Secondary outcomes

  1. OS Rate

    Overall survival rate

    Time frame: 6 months

  2. PFS

    Progression-free survival according to RECIST v1.1

    Time frame: Imaging assessment was performed on C1D28 and every 8 weeks after C1D28 until radiographic progressive disease (PD) was documented.

  3. TTR

    Time to response according to RECIST v1.1 (Response was assessed with CT or MRI using RECIST v1.1, Time to response (TTR): date of first dose to date of first documented CR or PR)

    Time frame: Imaging assessment was performed on C1D28 and every 8 weeks after C1D28 until radiographic progressive disease (PD) was documented.

  4. DoR

    Duration of response according to RECIST v1.1 (Response was assessed with CT or MRI using RECIST v1.1, Duration of response (DoR): DoR will only be performed in subjects who have a confirmed tumor response (CR or PR) after treatment

    Time frame: Imaging assessment was performed on C1D28 and every 8 weeks after C1D28 until radiographic progressive disease (PD) was documented.

  5. DCR

    Disease control rate according to RECIST v1.1 (Response was assessed with CT or MRI using RECIST v1.1; Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to\<10 mm; Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Disease control rate (DCR): CR+PR+SD

    Time frame: Imaging assessment was performed on C1D28 and every 8 weeks after C1D28 until radiographic progressive disease (PD) was documented.

  6. OS

    Overall survival

    Time frame: on average of 2 years

07

Results

Posted Aug 7, 2024

Participant flow

Participant flow — Overall Study
MilestoneA(SHR-1210+Apatinib)B(SHR-1210+Apatinib)C(SHR-1210+Apatinib)
Started4766
Completed4766
Not completed000

Outcome measures

PrimaryAdverse Event

Evaluation of adverse event rate according to CTCAE v4.03

Time frame:
24 months
Reported as:
Number · participants
Adverse Event
participantsA(SHR-1210+Apatinib)B(SHR-1210+Apatinib)C(SHR-1210+Apatinib)
Adverse Event4765
PrimaryORR

Objective response rate according to RECIST v1.1 (Response was assessed with CT or MRI using RECIST v1.1, Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to\<10 mm; Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Over all response:CR+PR)

Time frame:
6 months
Reported as:
Number · percentage of number of people in FAS
ORR
percentage of number of people in FASA(SHR-1210+Apatinib)B(SHR-1210+Apatinib)C(SHR-1210+Apatinib)
ORR34.0 (20.9 to 49.3)33.3 (4.3 to 77.7)33.3 (4.3 to 77.7)
SecondaryOS Rate

Overall survival rate

Time frame:
6 months
Reported as:
Number · percentage of number of people in FAS
OS Rate
percentage of number of people in FASA(SHR-1210+Apatinib)B(SHR-1210+Apatinib)C(SHR-1210+Apatinib)
OS Rate63.8 (48.4 to 75.7)66.7 (19.5 to 90.4)44.4 (6.6 to 78.5)
SecondaryPFS

Progression-free survival according to RECIST v1.1

Time frame:
Imaging assessment was performed on C1D28 and every 8 weeks after C1D28 until radiographic progressive disease (PD) was documented.
Reported as:
Median · months
PFS
monthsA(SHR-1210+Apatinib)B(SHR-1210+Apatinib)C(SHR-1210+Apatinib)
PFS3.6 (1.9 to 4.6)3.6 (2.7 to 8.3)1.2 (0.9 to 19.7)
SecondaryTTR

Time to response according to RECIST v1.1 (Response was assessed with CT or MRI using RECIST v1.1, Time to response (TTR): date of first dose to date of first documented CR or PR)

Time frame:
Imaging assessment was performed on C1D28 and every 8 weeks after C1D28 until radiographic progressive disease (PD) was documented.
Reported as:
Median · months
TTR
monthsA(SHR-1210+Apatinib)B(SHR-1210+Apatinib)C(SHR-1210+Apatinib)
TTR1.0 (0.9 to 4.7)1.8 (0.9 to 2.7)4.6 (0.9 to 8.2)
SecondaryDoR

Duration of response according to RECIST v1.1 (Response was assessed with CT or MRI using RECIST v1.1, Duration of response (DoR): DoR will only be performed in subjects who have a confirmed tumor response (CR or PR) after treatment

Time frame:
Imaging assessment was performed on C1D28 and every 8 weeks after C1D28 until radiographic progressive disease (PD) was documented.
Reported as:
Median · months
DoR
monthsA(SHR-1210+Apatinib)B(SHR-1210+Apatinib)C(SHR-1210+Apatinib)
DoR6.2 (3.7 to 9.2)4.2 (3.6 to 4.7)8.0 (4.6 to 11.5)
SecondaryDCR

Disease control rate according to RECIST v1.1 (Response was assessed with CT or MRI using RECIST v1.1; Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to\<10 mm; Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Disease control rate (DCR): CR+PR+SD

Time frame:
Imaging assessment was performed on C1D28 and every 8 weeks after C1D28 until radiographic progressive disease (PD) was documented.
Reported as:
Number · percentage of number of people in FAS
DCR
percentage of number of people in FASA(SHR-1210+Apatinib)B(SHR-1210+Apatinib)C(SHR-1210+Apatinib)
DCR68.1 (52.9 to 80.9)100.0 (54.1 to 100.0)50.0 (11.8 to 88.2)
SecondaryOS

Overall survival

Time frame:
on average of 2 years
Reported as:
Median · months
OS
monthsA(SHR-1210+Apatinib)B(SHR-1210+Apatinib)C(SHR-1210+Apatinib)
OS8.8 (4.9 to 12.3)11.2 (4.9 to NA)5.4 (1.5 to NA)

Adverse events

Collected over 24 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
A(SHR-1210+Apatinib)17/47 (36.2%)27/47 (57.4%)47/47 (100%)
B(SHR-1210+Apatinib)1/6 (16.7%)4/6 (66.7%)6/6 (100%)
C(SHR-1210+Apatinib)2/6 (33.3%)2/6 (33.3%)5/6 (83.3%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventA(SHR-1210+Apatinib)B(SHR-1210+Apatinib)C(SHR-1210+Apatinib)
Aspartate aminotransferase increasedInvestigations3/472/60/6
Alanine aminotransferase increasedInvestigations2/472/60/6
HemoptysisRespiratory, thoracic and mediastinal disorders1/472/60/6
DeathGeneral disorders9/471/60/6
Progressive diseaseGeneral disorders6/470/61/6
Platelet count decreasedInvestigations4/471/60/6
Gamma-glutamyltransferase increasedInvestigations0/471/60/6
Blood alkaline phosphatase increasedInvestigations0/471/60/6
PneumoniaInfections and infestations3/471/60/6
Respiratory tract infectionInfections and infestations0/471/60/6
Most frequent other events
Showing 10 of 105
Most frequent other events
EventA(SHR-1210+Apatinib)B(SHR-1210+Apatinib)C(SHR-1210+Apatinib)
HypertensionVascular disorders28/476/63/6
Aspartate aminotransferase increasedInvestigations28/474/65/6
AstheniaGeneral disorders13/473/64/6
White blood cell count decreasedInvestigations20/474/62/6
Neutrophil count decreasedInvestigations14/474/62/6
Occult blood positiveInvestigations4/474/60/6
VomitingGastrointestinal disorders6/471/63/6
Alanine aminotransferase increasedInvestigations22/472/63/6
Platelet count decreasedInvestigations20/473/61/6
Blood creatinine increasedInvestigations6/473/61/6

Baseline characteristics

Age, Continuous
Age, Continuous(years)A(SHR-1210+Apatinib)B(SHR-1210+Apatinib)C(SHR-1210+Apatinib)Total
Mean60.3 ± 6.3659.3 ± 7.3954.2 ± 10.6859.6 ± 7.08
Sex: Female, Male
Sex: Female, Male(Participants)A(SHR-1210+Apatinib)B(SHR-1210+Apatinib)C(SHR-1210+Apatinib)Total
Female7018
Male406551
Race (NIH/OMB)
Race (NIH/OMB)(Participants)A(SHR-1210+Apatinib)B(SHR-1210+Apatinib)C(SHR-1210+Apatinib)Total
American Indian or Alaska Native0000
Asian476659
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)A(SHR-1210+Apatinib)B(SHR-1210+Apatinib)C(SHR-1210+Apatinib)Total
China476659
08

Study locations

2 sites
  • Cancer Hospital Chinese Academy of Medical Science
    Beijing, Beijing 100021, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
09

References and documents

Publications

  • Fan Y, Zhao J, Wang Q, Huang D, Li X, Chen J, Fang Y, Duan J, Zhou C, Hu Y, Yang H, Hu Y, Zhou J, Lin X, Wang L, Wang Z, Xu Y, Zhang T, Shi W, Zou J, Wang J. Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial. J Thorac Oncol. 2021 Feb;16(2):299-309. doi: 10.1016/j.jtho.2020.10.002. Epub 2020 Nov 6. PubMed 33166719 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Aug 2021, 39 months.

Results were first posted in Aug 2024, 3 years after primary completion.

Of 54 industry-sponsored phase 2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 44. This study's 39 months is above that.

Counting every sponsor, half of 204 studies reached it within 46 months; a quarter within 29 and three quarters within 84.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2018
First posted
Jan 31, 2018
StartActual
Apr 20, 2018
Primary completionActual
Aug 4, 2021
CompletionActual
Aug 4, 2021
Results first posted
Aug 7, 2024
Last update
Aug 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03417895
Responsible party
Sponsor
First posted
Jan 31, 2018
Start date
Apr 20, 2018
Primary completion
Aug 4, 2021
Completion
Aug 4, 2021
Results posted
Aug 7, 2024
Last update
Aug 7, 2024

Study contacts

Wei Shi
study director · Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Camrelizumab

Start the discussion